Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Evidence-based classification of genes implicated in craniosynostosis disorders using the ClinGen curation framework.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Gene Portals: A Framework for Integrating Clinical, Functional, and Structural Evidence into Rare Disease Variant Classification.

medRxiv : the preprint server for health sciences·2026
Same author

Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.

Therapeutic advances in rare disease·2026
Same author

Prioritizing topics for a clinical practice guideline on SATB2-associated syndrome: methodological rigor vs clinical usability.

Journal of clinical epidemiology·2026
Same author

Functional characterization of pathogenic SATB2 missense variants identifies distinct effects on chromatin binding and transcriptional activity.

HGG advances·2025
Same author

A clinical and genotype-phenotype analysis of MACF1 variants.

American journal of human genetics·2025
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Jun 28, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

La enfermedad de Fabry es la enfermedad de Fabry.

Yuri A Zarate1, Robert J Hopkin

  • 1Cincinnati Children's Hospital Medical Center, Division of Human Genetics, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Lancet (London, England)
|October 23, 2008
PubMed
Resumen
Este resumen es generado por máquina.

La enfermedad de Fabry, un trastorno genético, es el resultado de mutaciones en el gen GLA que causan deficiencia de alfa-galactosidasa A. La terapia temprana de reemplazo enzimático mejora la función y los síntomas de los órganos, pero pueden ser necesarios tratamientos adicionales para la disfunción de los órganos.

Más Videos Relacionados

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

Videos de Experimentos Relacionados

Last Updated: Jun 28, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

Área de la Ciencia:

  • Genética La genética.
  • Trastornos metabólicos Los trastornos metabólicos son trastornos metabólicos que se producen en el cuerpo.
  • Enfermedades de almacenamiento lisosomal.

Sus antecedentes:

  • La enfermedad de Fabry es un trastorno de almacenamiento lisosómico ligado a X derivado de mutaciones en el gen GLA.
  • Esta deficiencia en alfa-galactosidasa A causa la acumulación de glucosfingolipidos, lo que lleva a una morbilidad y mortalidad significativas.
  • La revisión abarca la epidemiología, la fisiopatología, las manifestaciones clínicas, el diagnóstico, el manejo, la prevención y los impactos en la calidad de vida.

Objetivo del estudio:

  • Para proporcionar una visión general completa de la enfermedad de Fabry.
  • Para resaltar la importancia de la terapia temprana de reemplazo enzimático (ERT).
  • Para discutir la necesidad de estrategias de tratamiento individualizadas junto con ERT.

Principales métodos:

  • Revisión de la literatura sobre los aspectos de la enfermedad de Fabry.
  • Análisis de las estrategias de tratamiento actuales, incluyendo ERT.
  • Evaluación de los resultados clínicos y los datos de calidad de vida.

Principales resultados:

  • La ERT ha demostrado ser prometedora para mejorar la masa cardíaca, estabilizar la función renal y aliviar el dolor, la sudoración, los síntomas gastrointestinales, auditivos y pulmonares.
  • La iniciación temprana de la ERT es crucial para obtener mejores resultados en los principales órganos afectados.
  • Muchos pacientes requieren tratamientos adicionales específicos de los síntomas, particularmente aquellos con disfunción orgánica existente.

Conclusiones:

  • La terapia de reemplazo enzimático es una piedra angular en el manejo de la enfermedad de Fabry, especialmente cuando se inicia temprano.
  • Un enfoque de tratamiento multimodal, que combina la ERT con terapias sintomáticas específicas, a menudo es necesario para una atención óptima del paciente.
  • Se necesita más investigación para establecer la eficacia y los resultados del tratamiento a largo plazo.